Entity

Time filter

Source Type

Limoges, France

Beuselinck B.,University Hospitals Leuven | Beuselinck B.,French Institute of Health and Medical Research | Karadimou A.,French Institute of Health and Medical Research | Lambrechts D.,Catholic University of Leuven | And 21 more authors.
British Journal of Cancer | Year: 2013

Background:There are no validated markers that predict response in metastatic renal cell cancer (RCC) patients treated with sunitinib. We aim to study the impact of single-nucleotide polymorphisms (SNPs) that have recently been proposed as predictors of outcome to anti-VEGF-targeted therapy in metastatic RCC in an independent cohort of patients.Methods:We genotyped 16 key SNPs in 10 genes involved in sunitinib pharmacokinetics, pharmacodynamics and VEGF-independent angiogenesis in patients with metastatic clear-cell RCC treated with sunitinib as the first-line targeted therapy. Association between SNPs, progression-free survival (PFS) and overall survival (OS) were studied by multivariate Cox regression using relevant clinical factors associated with PFS and OS as covariates.Results:In a series of 88 patients, both PFS and OS were associated significantly with SNP rs1128503 in ABCB1 (P=0.027 and P=0.025), rs4073054 in NR1/3 (P=0.025 and P=0.035) and rs307821 in VEGFR3 (P=0.032 and P=0.011). Progression-free survival alone was associated with rs2981582 in FGFR2 (P=0.031) and rs2276707 in NR1/2 (P=0.047), whereas OS alone was associated with rs2307424 in NR1/3 (P=0.048) and rs307826 in VEGFR3 (P=0.013).Conclusion: Our results confirm former communications regarding the association between SNPs in ABCB1, NR1/2, NR1/3 and VEGFR3 and sunitinib outcome in clear-cell RCC. Prospective validation of these SNPs is now required. © 2013 Cancer Research UK. Source


Sassolas B.,Hopital Cavale Blanche | Mourregot A.,Institute Du Cancer Of Montpellier Val Daurelle | Thariat J.,Center Antoine Lacassagne | Tiffet O.,Jean Monnet University | And 15 more authors.
Bulletin du Cancer | Year: 2014

Introduction. the last years are marked by the emergence of new molecules for the treatment of metastatic cutaneous melanoma with a significant benefit on the survival. Besides, some techniques are in development for the loco-regional treatment of the metastatic sites, bringing new therapeutic perspectives. However, their respective use and place in the therapeutic strategy are debated by healthcare professionals. Objective. the French National Cancer Institute leads a national clinical practice guidelines project since 2008. It realized a review of these modalities of treatment and developed recommendations. Methods. the clinical practice guidelines development process is based on systematic literature review and critical appraisal by a multidisciplinary expert workgroup. The recommendations are thus based on the best available evidence and expert agreement. Prior to publication, the guidelines are reviewed by independent practitioners in cancer care delivery. Results. this article presents recommendations for loco-regional treatments of the pulmonary, bone, cutaneous, hepatic and digestive metastatic sites for patients with pauci-metastatic cutaneous melanoma. Copyright © 2007 John Libbey Eurotext - All rights reserved. Source


Aubert M.,Sanofi S.A. | Beytout J.,Service des Maladies Infectieuses et Tropicales | Callamand P.,Center Hospitalier Of Beziers | Cheymol J.,Cabinet Medical | And 24 more authors.
Archives de Pediatrie | Year: 2013

Every year, the National Foundation for Infectious Diseases brings together more than 300 participants to review progress in vaccine research and development and identify the most promising avenues of research. These conferences are among the most important scientific meetings entirely dedicated to vaccine research for both humans and animals, and provide a mix of plenary sessions with invited presentations by acknowledged international experts, parallel sessions, poster sessions, and informal exchanges between experts and young researchers. During the Fifteenth Conference that took place in Baltimore in May 2012, various topics were addressed, including the scientific basis for vaccinology; exploration of the immune response; novel vaccine design; new adjuvants; evaluation of the impact of newly introduced vaccines (such as rotavirus, HPV vaccines); vaccine safety; and immunization strategies. The new techniques of systems biology allow for a more comprehensive approach to the study of immune responses in order to identify correlates of protection and to design novel vaccines against chronic diseases such as AIDS or malaria, against which natural immunity is incomplete. © 2013 Published by Elsevier Masson SAS. Source


Labarde S.,Limoges University Hospital Center | Bugeaud J.-L.,Hopital Dupuytren | Nouaille Y.,Hopital Dupuytren
Actualites Pharmaceutiques | Year: 2013

The Medical Agency of Doping Prevention (AMPD) in Limousin regularly receives enquiries from athletes, health professionals or sports associations. It provides answers and advice. © 2012 Elsevier Masson SAS. Tous droits réservés. Source


Sparsa A.,Hopital Dupuytren | Sparsa A.,University of Monastir | Faucher K.,University of Monastir | Sol V.,Laboratoire Of Chimie Des Substances Naturelles | And 12 more authors.
Anticancer Research | Year: 2010

The large number of studies devoted to the effect of ultraviolet light on biological systems, contrasts with the lack of experimental data concerning the direct effects of visible light. It has been shown that blue light inhibited the growth of B16F10 melanoma cell lines and reduced the percentage of S phase cells. Yet these effects are poorly understood. Materials and Methods: Two cell lines and irradiation with blue light were used. Cell mortality and a possible mechanism of action were investigated. Results: Exposure of B16F10 melanoma and bovine endothelial cells to blue light (wavelength 450 nm, 10 J/cm2 from a Waldman lamp) induced a rapid and large reduction in viability followed by the death of virtually all the irradiated cells within 24 h. These results led us to expose a patient with haemorrhagic cutaneous melanoma metastasis to blue light. Irradiation led to an immediate arrest of haemorrhage, an inhibition of tumour growth and extensive tumour necrosis 24h after irradiation. Conclusion: Exposure to blue light may offer new appproaches to the treatment of superficial skin carcinomas in humans. Source

Discover hidden collaborations